D-0649-2020 Class II Terminated

Recalled by Appco Pharma LLC — Piscataway, NJ

FDA drug recall D-0649-2020 was initiated by Appco Pharma LLC on Jan 7, 2020 and is designated Class II. Reason for recall: CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API The recall status is terminated (terminated Apr 24, 2020). Affected quantity: 624 bottes.

Recall details

Product Type
Drugs
Report Date
Jan 15, 2020
Initiation Date
Jan 7, 2020
Termination Date
Apr 24, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
624 bottes

Product description

Ranitidine Capsules 150 mg, (a) 60 count bottles (NDC 62559-690-60) , (b) 500 count bottles (NDC 62559-690-05), Rx only, Manufactured by: Appco Pharma LLC, Piscataway, NJ 08854, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623.

Reason for recall

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Distribution pattern

Product was distributed to 6 major distributors/wholesalers some with multiple locations who may have further distribute the product.

Code information

Batch # 1905225VN, exp. date Apr-2021 1905226VD, exp. date Apr-2021 1906295UN, exp. date May-2021 1906296UN, exp. date May-2021 1906297UN, exp. date May-2021 1906298UD, exp. date May-2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0649-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0649-2020. Report a data issue: hello@regdatalab.com.